Journal of Clinical Immunology

, 31:900

Individual Antibody and T Cell Responses to Vaccination and Infection with the 2009 Pandemic Swine-Origin H1N1 Influenza Virus

  • Gillian M. Air
  • JingQi Feng
  • Tao Chen
  • Michelle L. Joachims
  • Judith A. James
  • Linda F. Thompson
Article

Abstract

Introduction

The 2009 swine-origin H1N1 influenza virus (swH1N1) provided an opportunity to study immune responses to a new influenza strain in the context of seasonal influenza vaccination. Our goals were: to assess whether analyzing multiple parameters of immune responsiveness to influenza has an advantage over evaluating hemagglutination inhibition (HAI) titer alone, to determine whether vaccination with the seasonal vaccine induced cross-reactive immunity to swH1N1 in some individuals, and to determine whether the immune response against swH1N1 is higher after infection than vaccination.

Methods

Antibody and T cell responses were studied in ten subjects who were first immunized with the 2009–2010 seasonal influenza subunit vaccine, then 6 weeks later with the swH1N1 monovalent subunit vaccine. The amount of antibody against native virus glycoproteins, overall avidity of these antibodies, and HAI titer were measured. T cells were evaluated for proliferation and IFNγ secretion in response to the vaccine in vitro. Individuals with influenza-like illness were also evaluated, adding a microplate neuraminidase inhibition (NAI) test.

Results

The immune response to influenza was highly variable and immune parameters did not increase in parallel. The seasonal vaccine induced antibodies recognizing the pandemic virus in 50% of subjects. Antibody affinity and NAI activity to swH1N1 were higher after natural infection than vaccination.

Conclusions

The evaluation of several immune parameters gives a more complete measure of immune responsiveness to influenza infection or vaccination than the HAI test alone.

Keywords

Pandemic 2009 H1N1 influenza vaccine response antibodies T cells after infection 

Abbreviations

APC

Allophycocyanin

CFSE

Carboxyfluorescein succinimidyl ester

HA

Hemagglutinin

ILI

Influenza-like illness

NA

Neuraminidase

swH1N1

Swine-origin 2009 pandemic H1N1 human influenza virus

Supplementary material

10875_2011_9563_MOESM1_ESM.ppt (192 kb)
Supplemental Fig. 1Individual antibody and T cell responses to immunization with the seasonal and swH1N1 influenza vaccines. All subjects were immunized with the 2009–2010 seasonal trivalent subunit influenza vaccine and with the swH1N1 vaccine approximately 6 weeks later. Blood samples were obtained on the days of vaccination (blood draws 1 and 3) and 2 weeks after each vaccination (blood draws 2 and 4). Antibody responses were evaluated by measuring Bmax, Ka, and HAI at each time point. T cell responses were assessed by measuring IFNγ production by ELISPOT and proliferation by CFSE dye dilution after culturing PBMCs in vitro with the vaccines. The blood draws are labeled “1, 2, 3, and 4” across the bottom of each panel and HAI is plotted as number of wells showing HA inhibition as in Fig. 1. (PPT 192 kb)

References

  1. 1.
    Gibbs AJ, Armstrong JS, Downie JC. From where did the 2009 ‘swine-origin’ influenza A virus (H1N1) emerge? Virol J. 2009;6:e207.CrossRefGoogle Scholar
  2. 2.
    Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197–201.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith GJD, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459:1122–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328:357–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Gilbert GL, Cretikos MA, Hueston L, Doukas G, O'Toole B, Dwyer DE. Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS ONE. 2010;5:e12562.PubMedCrossRefGoogle Scholar
  7. 7.
    Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, Broman M, et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill. 2010;15(5):pii=19478.PubMedGoogle Scholar
  8. 8.
    Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375:1100–8.PubMedCrossRefGoogle Scholar
  9. 9.
    McCullers JA, Van De Velde L-A, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis. 2010;50:1487–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Zimmer SM, Crevar CJ, Carter DM, Stark JH, Giles BM, Zimmerman RK, et al. Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS ONE. 2010;5:e11601.PubMedCrossRefGoogle Scholar
  11. 11.
    Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J. 2007;4:42.PubMedCrossRefGoogle Scholar
  12. 12.
    Gulati S, Smith DF, Air GM. Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses. Virol J. 2009;6:22.PubMedCrossRefGoogle Scholar
  13. 13.
    Subbarao EK, Kawaoka Y, Ryan-Poirier K, Clements ML, Murphy BR. Comparison of different approaches to measuring influenza A virus-specific hemagglutination inhibition antibodies in the presence of serum inhibitors. J Clin Microbiol. 1992;30:996–9.PubMedGoogle Scholar
  14. 14.
    Gulati U, Keitel WA, Air GM. Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza Other Respir Viruses. 2007;1:147–56.CrossRefGoogle Scholar
  15. 15.
    Feng J, Gulati U, Zhang X, Keitel WA, Thompson DM, James JA, et al. Antibody quantity versus quality after influenza vaccination. Vaccine. 2009;27:6358–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Couch RB, Kasel J. Influenza. In: Lennette EH, Lennette DA, Lenette ET, editors. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. 7th ed. Washington, D.C.: American Public Health Association; 1995. p. 431–46.Google Scholar
  17. 17.
    Noah DL, Hill H, Hines D, White EL, Wolff MC. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clinical and vaccine immunology: CVI. 2009;16:558–66.PubMedCrossRefGoogle Scholar
  18. 18.
    Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ. 1973;48:199–202.PubMedGoogle Scholar
  19. 19.
    Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982;31:417–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Cate TR, Rayford Y, Niño D, Winokur P, Brady R, Belshe R, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010;28:2076–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005;23:1414–25.PubMedCrossRefGoogle Scholar
  22. 22.
    Chi C-Y, Liu C-C, Lin C-C, Wang H-C, Cheng Y-T, Chang C-M, et al. Pre-existing antibody response against 2009 pandemic influenza H1N1 viruses in Taiwanese population. Clinical and vaccine immunology: CVI. 2010;17:1958–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Mak GC, Choy PWW, Lee WY, Wong AH, Ng KC, Lim W. Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong. J Med Virol. 2010;82:1809–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Richards KA, Topham D, Chaves FA, Sant AJ. Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol. 2010;185:4998–5002.PubMedCrossRefGoogle Scholar
  25. 25.
    Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA. 2009;106:20365–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Del Giudice G, Stittelaar KJ, van Amerongen G, Simon J, Osterhaus ADME, Stöhr K, et al. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med. 2009;1:12re1.PubMedCrossRefGoogle Scholar
  27. 27.
    Min J-Y, Chen GL, Santos C, Lamirande EW, Matsuoka Y, Subbarao K. Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology. 2010;408:128–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E, Rubrum AM, Govorkova EA, et al. Impact of prior seasonal influenza vaccination and infection on pandemic A(H1N1) influenza virus replication in ferrets. Vaccine. 2010. doi:10.1016/j.vaccine.2010.08.067.
  29. 29.
    Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis. 2010;202:1327–37.PubMedCrossRefGoogle Scholar
  31. 31.
    Beigel JH, Voell J, Huang C-y, Burbelo PD, Lane HC. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis. 2009;200:501–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Hayden FG, Howard WA, Palkonyay L, Kieny MP. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12–13 February 2009. Vaccine. 2009;27:4079–89.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Gillian M. Air
    • 1
  • JingQi Feng
    • 1
  • Tao Chen
    • 1
  • Michelle L. Joachims
    • 2
  • Judith A. James
    • 3
  • Linda F. Thompson
    • 2
  1. 1.Department of Biochemistry and Molecular BiologyUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.Immunobiology and Cancer ProgramOklahoma Medical Research FoundationOklahoma CityUSA
  3. 3.Arthritis and Clinical Immunology ProgramOklahoma Medical Research FoundationOklahoma CityUSA

Personalised recommendations